Certolizumab pegol
Indications
Certolizumab pegol is used for:
Reducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Certolizumab pegol :
Mechanism of Action
Certolizumab pegol binds to free and membrane-bound human TNFa with a KD of 90pM and neutralizes its activity. Extent of neutralization is also dose-dependent. It also inhibited the release of lipopolysaccharide-induced IL-1A from monocytes. TNFa is a key pro-inflammatory cytokine with a central role in inflammatory processes in which elevated levels have been observed in patients with RA and Crohn's. Certolizumab pegol selectively neutralizes TNFa (IC90 of 4 ng/mL for inhibition of human TNFa in the in vitro L929 murine fibrosarcoma cytotoxicity assay). It does not bind to TNF-A. As certolizumab is only a Fab' fragment and thus missing the Fc region, it does not fix complement or cause antibody-dependent cell-mediated cytotoxicity. Furthermore, apoptosis of monocytes or lymphocytes, or neutrophil degranulation have not been observed in vitro.